Our Contact Information

To Sarcoma Gala

Tiffany presenting an overview of the progress we are making toward our goal of uniting communities across the country in the fight against sarcoma. Check out the list of upcoming events and get ready for an exciting year as our 2024 Race to Cure Sarcoma series kicks off in March.

The path to a cure is research - and with your support, we can accelerate the pace of discovery and take critical steps to advance treatments.

Patients and their families need our help more than ever, and the impact of your generosity is immeasurable. We are proud to have not one but two players representing SFA and Sarcoma during their respective teams' games. John Franklin Myers, #91 on the New York Jets, and Trent Williams, #71 on the San Francisco 49ers. Check out their cleats below.

Defying the Odds

Tiffany's Tenacious Battle with Sarcoma: A Journey of Resilience

Tiffany faced each challenge courageously, undergoing various surgeries and treatments to fight her battle with leiomyosarcoma, initially mistaken for a fibroid. Despite the odds, she refused to let cancer have her.

"I might have cancer, but I'm not going to let cancer have me," encapsulates her spirit. Her story reveals the tenacity of the human spirit and the transformative power of determination.

Learn More and Register Below

The researchers we have funded have made it their mission to develop improved treatment options for those affected by sarcoma. In collaboration with the esteemed CDRC Sarcoma Task Force.

Clinical Trials Corner

These results indicate that patients with high-stage FDCS may respond to treatment with enzalutamide, strontium ranelate, and aspirin. Additional criteria, including organ function and tumor burden, will be considered for phase III trials.

YH001 is an experimental antibody targeting the tumor growth factor alpha (TGF-alpha) receptor. In the first part, YH001 will be given at the recommended dose in combination with envafolimab with and/or without doxorubicin. In the second part, YH001 will be given at the recommended dose in combination with envafolimab for advanced or metastatic sarcoma. Additional criteria, including organ function, will be considered for phase III trials.

Wishing you all a joyful holiday season and a prosperous New Year.

The researchers we have funded have made it their mission to develop improved treatment options for those affected by sarcoma. In collaboration with the esteemed CDRC Sarcoma Task Force.

Immune checkpoint inhibitors (ICIs) in alveolar soft-part sarcoma (ASPS), an ultra-rare cancer, are investigational and not yet approved by the FDA.

Reflecting on a Year of Progress and Looking Ahead to 2024

2023 also marked a record-breaking year for our Race to Cure Sarcoma series. With $20 million invested in sarcoma research, and we remain the leading funder of sarcoma research. In total, SFA committed close to $1.5 million to advance research. Funds through our SFA Research Grant Program.

As we approach the end of another year, I am filled with gratitude for the incredible strides we have made in sarcoma research and care. The researchers we have funded have made it their mission to develop improved treatment options for those affected by sarcoma.

Investigational Nucleic Acid-Based Treatments

The researchers we have funded have made it their mission to develop improved treatment options for those affected by sarcoma. In collaboration with the esteemed CDRC Sarcoma Task Force.

The researchers we have funded have made it their mission to develop improved treatment options for those affected by sarcoma. In collaboration with the esteemed CDRC Sarcoma Task Force.

The researchers we have funded have made it their mission to develop improved treatment options for those affected by sarcoma. In collaboration with the esteemed CDRC Sarcoma Task Force.

The researchers we have funded have made it their mission to develop improved treatment options for those affected by sarcoma. In collaboration with the esteemed CDRC Sarcoma Task Force.

The researchers we have funded have made it their mission to develop improved treatment options for those affected by sarcoma. In collaboration with the esteemed CDRC Sarcoma Task Force.

The researchers we have funded have made it their mission to develop improved treatment options for those affected by sarcoma. In collaboration with the esteemed CDRC Sarcoma Task Force.

The researchers we have funded have made it their mission to develop improved treatment options for those affected by sarcoma. In collaboration with the esteemed CDRC Sarcoma Task Force.

The researchers we have funded have made it their mission to develop improved treatment options for those affected by sarcoma. In collaboration with the esteemed CDRC Sarcoma Task Force.